March 03, 2015 10:20 AM ET

Pharmaceuticals

Company Overview of FoldRx Pharmaceuticals, Inc.

Company Overview

FoldRx Pharmaceuticals, Inc. discovers and develops disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The company’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson's disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts. As of October 6, 2010, FoldRx Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

100 Acorn Park Drive

5th Floor

Cambridge, MA 02140

United States

Founded in 2003

Phone:

617-252-5500

Fax:

617-252-5501

Key Executives for FoldRx Pharmaceuticals, Inc.

FoldRx Pharmaceuticals, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
No similar companies available.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
No data available

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FoldRx Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.